Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons by Wright, E. J. et al.
Cardiovascular risk factors associated with















A.C. Penalva de Oliveira,
MD, PhD
W. Pumpradit, MD
J.C. Shlay, MD, MSPH





Objective: To determine factors associated with baseline neurocognitive performance in HIV-
infected participants enrolled in the Strategies for Management of Antiretroviral Therapy
(SMART) neurology substudy.
Methods: Participants from Australia, North America, Brazil, and Thailand were administered a
5-test neurocognitive battery. Z scores and the neurocognitive performance outcome measure,
the quantitative neurocognitive performance z score (QNPZ-5), were calculated using US norms.
Neurocognitive impairment was defined as z scores 2 in two or more cognitive domains. Asso-
ciations of test scores, the QNPZ-5, and impairment with baseline factors including demograph-
ics and risk factors for HIV-associated dementia (HAD) and cardiovascular disease (CVD) were
determined in multiple regression.
Results: The 292 participants had a median CD4 cell count of 536 cells/mm3, 88% had an HIV
viral load 400 copies/mL, and 92% were taking antiretrovirals. Demographics, HIV, and clinical
factors differed between locations. The mean QNPZ-5 score was 0.72; 14% of participants
had neurocognitive impairment. For most tests, scores and z scores differed significantly be-
tween locations, with and without adjustment for age, sex, education, and race. Prior CVD was
associated with neurocognitive impairment. Prior CVD, hypercholesterolemia, and hypertension
were associated with poorer neurocognitive performance but conventional HAD risk factors and
the CNS penetration effectiveness rank of antiretroviral regimens were not.
Conclusions: In this HIV-positive population with high CD4 cell counts, neurocognitive impairment
was associated with prior CVD. Lower neurocognitive performance was associated with prior
CVD, hypertension, and hypercholesterolemia, but not conventional HAD risk factors. The contri-
bution of CVD and cardiovascular risk factors to the neurocognition of HIV-positive populations
warrants further investigation. Neurology® 2010;75:864–873
GLOSSARY
AD  Alzheimer disease; ART  antiretroviral therapy; BP  blood pressure; CES-D  Center for Epidemiologic Studies–
Depression scale; CT  Color Trails; CVD  cardiovascular disease; FTT  Finger Tapping Test; GPB  Grooved Pegboard;
HAD  HIV-associated dementia; NCI  neurocognitive impairment; QNPZ-5  quantitative neurocognitive performance z
score; SMART  Strategies for Management of Antiretroviral Therapy; TG  Timed Gait.
In advanced untreated HIV disease, HIV-associated dementia (HAD) develops in approximately
15% of patients1 and combination antiretroviral therapy (ART) has effectively reduced the inci-
dence of HAD.2 The Strategies for Management of Antiretroviral Therapy (SMART) study ran-
domized participants to intermittent, CD4-guided ART or continuous ART.3 In a neurology
substudy, a neurocognitive test battery was administered. We hypothesized that neurocognitive
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performance would be superior in patients re-
ceiving continuous ART via its attendant bene-
fits upon both peripheral and CNS immunity.
We present a cross-sectional analysis of 292
HIV-infected persons coenrolled in the
SMART neurology substudy at sites in Aus-
tralia, North America, Brazil, and Thailand.
We sought to explore factors associated with
neurocognitive performance. These included
demographics, ART, HAD, and cardiovascu-
lar risk factors and cardiovascular disease
(CVD). In HIV-negative populations, smok-
ing,4 hypertension,5 high cholesterol,6 obesity,5
and diabetes5 are the cardiovascular risk fac-
tors associated with increased risk of poor
cognitive function, vascular dementia, and
Alzheimer disease (AD). Prior myocardial in-
farction,7 coronary artery bypass grafting,8
and stroke5 are also associated with poor cog-
nitive function. In HIV-positive populations,
diabetes has been associated with HAD,9 and
increased carotid intima media thickening10
has been associated with poorer neurocogni-
tive performance. CVD risk factors were com-
mon in the SMART study3: we hypothesized
that they would be associated with lower base-
line neurocognitive performance. We sought
to describe and compare neuropsychological
test results obtained in Australia, North
America, Brazil, and Thailand and hypothe-
sized that test scores, but not the standardized
z scores, would differ across locations.
METHODS Study design. The SMART study was an inter-
national randomized trial comparing continuous ART with
CD4-cell count guided, intermittent ART in HIV-infected per-
sons with CD4 cell count 350 cells/mm3. The neurocognitive
component of the SMART neurology substudy aimed to com-
pare the 2 study arms for changes in neurocognitive function
through follow-up. Baseline, month 6, and annual assessment of
neurocognitive functioning in 600 participants would have pro-
vided 80% power to detect a difference of 0.27 in the primary
outcome (change in the aggregate quantitative neurocognitive
performance z score, QNPZ-5, described below). The neurology
substudy commenced enrollment in July 2005. In January 2006,
enrollment and the intermittent CD4-guided ART strategy of
the SMART study were stopped due to increased risk of AIDS
and serious non-AIDS complications. The primary results of the
SMART study are published elsewhere.3 At the time of this pro-
tocol change, only 292 of the 600 planned substudy participants
were enrolled, and minimal follow-up data were available.
Forty-seven SMART study sites in Australia, North America,
Brazil, and Thailand participated in the substudy. All eligible
SMART participants were offered substudy coenrollment. Sub-
study eligibility criteria included age 18 years, and the abil-
ity to perform the study’s neurocognitive tests in the site
clinician’s judgment.
Standard protocol approvals, registrations, and patient
consents. Substudy approval was obtained by each site’s insti-
tutional review board. Patient information and consent forms
were translated into Thai, Portuguese, and Spanish, and back-
translated into English. All participants provided written in-
formed consent. The study was registered at clinical trials.gov:
NCT00432003.
Outcome measures. The study’s neurocognitive test battery
comprised the Grooved Pegboard (GPB) (dominant hand),11
Color Trails (CT) 1 and CT2,12 Timed Gait (TG),13 and Finger
Tapping Test (FTT) (nondominant hand).14 Details of these
tests can be found in appendix e-1 on the Neurology® Web site at
www.neurology.org. This test battery was chosen because it is
sensitive to changes observed in HIV-associated neurocognitive
disorders, brief, easy to administer and teach, and can be used
internationally where little formal Western education exists15;
our tests closely resemble the battery used in a large, randomized
ART HIV treatment study.16
For all 5 tests, the raw scores of each participant were stan-
dardized to z scores by subtracting the mean test scores of
matched, HIV-negative reference populations, and dividing by
the reference SD. Therefore, z scores estimate how many SDs a
test score is above or below the average score of the reference
population; negative z scores denote below-average performance.
For the TG, raw scores were standardized to z scores using previ-
ously published reference distributions,13 matched by education
level. For the other tests, z scores were calculated using scoring
software by Psychological Assessment Resources, Inc., Odessa,
FL.17 Reference distributions were matched by education level
for all 5 tests, and additionally by age, sex, and race/ethnicity for
GPB and FTT,18 and by age for CT. All reference populations
were obtained in the United States.
Our primary neurocognitive performance outcome measure
was the QNPZ-5, calculated as the average of the 5 z scores from the
individual tests in the battery. A QNPZ-5 score below 0 denotes
below-average neurocognitive performance. For the purpose of this
study, we defined neurocognitive impairment (NCI) as z scores
2 in at least 2 cognitive ability domains. Ability domains as-
sessed were 1) speed/fine motor skills (GPB and FTT), 2) attention/
speed of processing (CT1), 3) abstraction/executive function
(CT2), and 4) gross motor skills (TG). The cutoff was chosen to
reflect criteria for abnormal neurocognitive performance that are a
required component for the diagnosis of HAD.19
We administered the Center for Epidemiologic Studies–De-
pression scale (CES-D)20 to screen for depression at baseline. The
CES-D has been used in international studies in HIV-infected15
populations. We used the recommended cutoff score of 16 to
define depression (sensitivity 86%–100%, specificity 53%–84%).21
Neuropsychological tests and the CES-D were administered
to participants by site staff, including medical practitioners, spe-
cialists, and nurses. Site staff underwent centralized training and
certification in the United States and Australia. Training was led
by a neuropsychologist or neurologist and an infectious disease
physician. Each trainee was required to administer the full test
battery during training, and at least 3 times afterwards to non-
study participants before administering it to study participants.
Test instructions and training materials were available for site
staff on the study Web site. Neuropsychological test instructions
were translated into Portuguese, Spanish, and Thai. We used
published translations of the Spanish22 and Brazilian Portu-
guese23 CES-D and an online Thai24 translation.
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Baseline data collected within the parent SMART study in-
cluded demography, HIV history, general medical history, and lab-
oratory values (summarized in table 1 and table e-1); additionally,
alcohol and drug use were collected within the substudy. We sum-
marized risk factors for CVD into a modified Framingham score;
since blood pressure (BP) was not available, we assigned a systolic
BP of 140 mm Hg to participants using antihypertensive drugs, and
120 mm Hg otherwise.25 We calculated the CNS penetration effec-
tiveness rank26 of patients’ ART regimens.
Statistical methods. Baseline characteristics, neuropsycholog-
ical test scores, and CES-D scores were summarized by location
of enrollment. The Kruskal-Wallis rank sum test was used to
compare median values across locations, 2 tests to compare per-
centages. Mean test scores (raw scores and z scores) were com-
pared across locations using analysis of variance and the Tukey
Honest Significant Difference pairwise comparison method. In
order to account for variability between clinical sites within
countries, we also compared locations in hierarchical mixed ef-
fects models with sites nested in location.
Associations of baseline factors with raw test scores, z scores,
the QNPZ-5 score, and having z scores 2 in 2 or more cog-
nitive domains (a total of 12 outcomes) were determined by
multiple linear or logistic regression. In a first step, the following
factors were included: HAD risk factors (age, current and nadir
Table 1 Baseline characteristics by location
Characteristics
Total (n  292)
% or median (IQR)










Age, y 40 (35–45.5) 43 42 38 0.001a
Female 41.8 18.6 37.8 59.3 0.001a
Race/ethnicity 0.001a
Asian 50.7 2.0 2.2 100.0
Black 19.5 45.1 24.5 0
Other or unknown 29.8 52.9 73.3 0
Education (% with <12 y) 53.8 40.2 75.6 56.6 0.001a
HIV-related factors
CD4 count, cells/mm3 536 (437–693) 522 628 517 0.003a
Nadir CD4 count, cells/mm3 225 (158–296) 208 234 226 0.99
HIV RNA <400 copies/mL 87.6 69.6 88.6 100.0 0.001a
Prior AIDS diagnosis 20.9 26.5 44.4 9.7 0.001a
Preexisting conditions
CVDb 3.4 5.9 4.4 1.4 0.15
Diabetes 3.8 4.9 4.4 2.8 0.66
ART use at baseline
Years of prior ART use 4 (3–6) 5 6 3 0.001a
Current ART use 92.5 82.4 97.8 97.9 0.001a
CNS penetration
effectiveness rankc
1.5 (1.5–2.0) 1.5 2.0 1.5 0.001a
Cardiovascular risk factors
Total cholesterol, mg/dL 196 (168–222) 190 180 203 0.02a
HDL cholesterol, mg/dL 44 (36–54) 41 37 49 0.001a
Lipid-lowering drugs 8.6 18.6 6.7 2.1 0.001a
Blood pressure–lowering
drugs
11.0 21.6 13.3 2.8 0.001a
Body mass index, kg/m2 23.5 (21.1–26.6) 25.1 24.2 22.2 0.001a
Current smoking 23.3 44.1 13.3 11.7 0.001a
Recreational drug use 5.5 13.7 2.2 0.7 0.001a
Predicted 10-y risk of CVDd
(% per 10 y)
3 (2–7) 5 4 3 0.001a
Abbreviations: ART  antiretroviral therapy; CVD  cardiovascular disease; HDL  high-density lipoprotein; IQR  inter-
quartile range.
a Significant.
b Previous myocardial infarction (4), stroke (0), coronary heart disease (3), congestive heart failure (2), or peripheral vascu-
lar disease (5).
c Calculated using the CNS Penetration Effectiveness Rank.26
d Calculated using the Framingham score.25
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CD4 cell counts, prior AIDS, diabetes); sex; race/ethnicity; loca-
tion of enrollment; education; body mass index; smoking; alco-
hol abuse; recreational drug use; history of hepatitis B, hepatitis
C, or CVD; viral load (HIV RNA 400 copies/mL); CNS pen-
etration effectiveness rank; use of BP-lowering and lipid-
lowering drugs; total cholesterol, high-density lipoprotein, and
low-density lipoprotein; and CES-D score 16. Factors were
then eliminated using backwards selection with the Akaike infor-
mation criterion. We retained age, gender, race, and education
in all models, because these factors were associated with neuro-
psychological test results in noninfected populations, and refer-
ence norms for calculating z scores are usually matched by these
factors. We also retained location to consistently assess the loca-
tion effect. Coefficients and p values from the final models were
presented. In a separate model, lipids and use of BP-lowering
drugs were replaced by Framingham risk estimates for CVD (4
categories),25 extrapolating BP from use of BP-lowering drugs.
Analyses were performed using SAS version 9.2 (SAS Insti-
tute, Cary, NC) and R version 2.9. All tests were 2-sided. p
Values 0.05 were considered significant.

























GPB, s 72.7  25.8 83.9 70.4 65.5 0.001d 4.0 23.0 0.004d
CT1, s 49.5  22.5 48.8 60.2 46.7 0.002d 7.9 21.5 0.27
CT2, s 98.6  43.0 92.3 127.1 94.1 0.001d 15.8 40.2 0.08
TG, s 11.9  2.1 11.8 11.2 12.1 0.04d 0.8 2.0 0.51
FTT, taps 39.4  7.9 39.8 42.7 38.1 0.002d 3.7 7.4 0.45
z Scores,e
mean  SD
GPB 0.26  1.19 0.62 0.04 0.08 0.001d 0.22 1.10 0.04d
CT1 0.63  1.42 0.63 1.16 0.47 0.02d 0.53 1.35 0.50
CT2 0.15  1.27 0.06 0.85 0.00 0.001d 0.50 1.19 0.20
TG 1.60  1.74 1.60 0.94 1.82 0.01d 0.58 1.62 0.29
FTT 0.96  1.10 1.09 0.41 1.04 0.001d 0.45 1.04 0.25
QNPZ-5, mean  SD 0.72  0.84 0.80 0.68 0.68 0.53 0.35 0.79 0.81
No. (%) with z
scores <1 in 2 or
more independent
domains
150 (51.4) 52 (51.0) 18 (40.0) 80 (55.2) 0.21
NCI: No. (%) with z
scores <2 in 2 or
more independent
domains
42 (14.4) 23 (22.5) 5 (11.1) 14 (9.7) 0.01d




71 (25.5) 38 (41.3) 14 (31.1) 19 (13.5) 0.001d
Abbreviations: CES-D  Center for Epidemiologic Studies–Depression scale; CT  Color Trails; FTT  Finger Tapping Test
(nondominant hand); GPB  Grooved Pegboard (dominant hand); NCI  neurocognitive impairment; QNPZ-5  quantitative
neurocognitive performance z score; TG  Timed Gait.
a Test scoring: GPB: time in seconds. CT1 and 2 tests: time in seconds. TG: 3 timed trials; scored as average time per trial, in
seconds. FTT: each participant performed between 5 and 10 trials. The test score was the average of the 5 trials where the
number of taps had the least spread. Outliers: We capped the time recorded for the GPB test at 300 seconds and for TG at
45 seconds (1 participant each). Test scores that corresponded to z scores that were more than 11 SD above or below the
reference mean were considered recording errors and deleted from the analysis (1 CT1, and 2 TG records).
b Differences between locations were tested in an analysis of variance model.
c Differences between locations were tested in a mixed effects hierarchical model, with random effects for sites, nested in
location, and fixed effects for the 3 locations. This analysis includes 272 participants at 15 sites (Australia 14/1, North
America 68/7, Brazil 45/2, Thailand 145/5); clinical sites with less than 5 participants were pooled by city, or by country, or
deleted.
d Significant.
e z Scores were standardized by subtracting the mean of reference distributions (test scores of healthy individuals
matched for education all tests, age GPB, CT, FTT, gender GPB, FTT, race/ethnicity GPB, FTT), and dividing by the
reference distribution’s standard deviation. In all locations, mean z scores were below 0 ( p  0.001); z scores below 0
denote below-average performance.
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RESULTS Baseline characteristics. Baseline charac-
teristics of the 292 study participants by their location
of enrollment are shown in table 1 and table e-1. Partic-
ipant characteristics differed across locations, including
their demographics, HIV, and general medical history.
Baseline neurocognitive test scores are summa-
rized by location in table 2 and the figure. Overall,
the mean QNPZ-5 score was 0.72; in each loca-
tion, the mean z score was below 0 (p  0.001),
denoting below-average performance compared to a
healthy, matched population. Fourteen percent of
patients met the study definition of NCI (z scores
2 in 2 or more cognitive domains); 51% of par-
ticipants had z scores 1 in 2 or more cognitive
domains. For each of the 5 tests, mean z scores dif-
fered between locations (all p  0.02). There was no
evidence, however, for regional differences in mean
QNPZ-5 scores (p  0.53), and no one region per-
formed consistently higher or lower across all tests. In
pairwise comparisons, there were no significant differ-
ences in test scores between Australia/North America
and Thailand, except for the GPB (figure). Table 2 also
shows the variability in test scores between clinical sites
(between-site SD) in relation to the between-patient
SD, estimated in hierarchical mixed models. For all tests
except GPB, the between-site SD was about one-third
to one-half of the between-patient SD, and remaining
differences between locations (countries) were not sta-
tistically significant relative to the differences between
sites (p  0.05 in the hierarchical models).
The mean CES-D score was 11.2. Overall, 71
participants (26%) met the study definition of de-
pression (table 2). The proportion of participants
with depression was highest in Australia/North
America (41%) and lowest in Thailand (14%).
Association between baseline factors and neurocogni-
tive performance. The z scores for all 5 tests, but not
Figure z Scores and summary QNPZ-5 for 5 neuropsychological tests, by location
Box plots show the distributions of baseline z scores of 292 participants; 102 participants were enrolled in Australia and North America, 45 in Brazil, and
145 in Thailand. Brackets below the location labels connect pairs of locations where mean scores are not significantly different. Boxes show the interquar-
tile range; the horizonta line in the box denotes the median; the diamond denotes the mean. Whiskers extend 1.5 times the interquartile range above and
below the z score quartiles. Circles denote outliers. Au  Australia; Br  Brazil; CT  Color Trails Test; FT  Finger Tapping Test; GPB  Grooved Pegboard
Test; NA  North America; QNPZ-5  quantitative neurocognitive performance z score; TG  Timed Gait Test; Thai  Thailand.
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the QNPZ-5 scores, differed by location after adjust-
ment for age, gender, race/ethnicity, education, and
selected other factors (table 3). Older age was associ-
ated with worse test performance in raw test scores
except for TG, but not with any of the z scores,
which are standardized by age. Women and black
participants had lower estimated mean QNPZ-5
scores (by 0.21 and 0.48) after adjustment for the
other covariates.
Patients with preexisting CVD had 6.2-fold
higher odds of having NCI (p  0.01, 95% CI 1.4–
26.4), after adjustment for age, gender, race/ethnic-
ity, education, location, prior AIDS, and total
cholesterol (table 3). Prior CVD was also associated
with lower QNPZ-5 scores (by 0.7; p  0.02), as
were use of antihypertensive agents (by 0.4, p 
0.03), higher total cholesterol (by 0.03 per 10 mg/
mL, p  0.02), and hepatitis B (by 0.7, p  0.05);
estimated mean QNPZ-5 scores were lower for
women, black participants, and, borderline, for those
with depression (p  0.07) (table 3). Smoking, dia-
betes, higher body mass index, higher low-density
lipoprotein, and use of lipid-lowering drugs were not
independently associated with NCI or lower
QNPZ-5 scores but were associated with lower z
scores or worse test scores for some of the tests (table
3 and table e-2). Higher high-density lipoprotein was
associated with lower z scores on GPB and CT1, but
not with NCI or QNPZ-5 scores. In a sensitivity
analysis, we included the Framingham CVD risk
score as a factor instead of fitting cholesterol and BP-
lowering drugs separately: there was no evidence for
an association of the Framingham score with either
the QNPZ-5 or NCI (data not shown). There was
no evidence that major abnormalities on the baseline
ECG, hepatitis C, or alcohol abuse were indepen-
dently associated with any of the neurocognitive per-
formance measures (table 3, footnote).
There was no evidence for an association of base-
line or nadir CD4 cell counts, viral load, diabetes, or
the CNS penetration effectiveness rank of ART regi-
mens with QNPZ-5 scores or NCI.
DISCUSSION Our cross-sectional study of baseline
neurocognitive performance included 292 SMART
study participants from Australia, North America,
Brazil, and Thailand with CD4 cell counts 350
cells/mm3. At baseline, 14% of participants had NCI
and prior CVD was the single associated factor. Par-
ticipants with prior CVD, higher total cholesterol,
and those using antihypertensive drugs had lower es-
timated mean baseline neurocognitive performance,
but neither HIV-related risk factors commonly asso-
ciated with HAD nor the CNS penetration effective-
ness rank of ART were associated with NCI or
neurocognitive performance measured by the
QNPZ-5. The 10 participants (3.4%) with prior
CVD in our study had experienced myocardial in-
farction, coronary heart disease, congestive heart fail-
ure, or peripheral vascular disease, but not stroke.
Our findings suggest that cardiovascular risk
factors and disease may be key drivers of impair-
ment in HIV-positive persons with high CD4 cell
counts, more so than HIV-related HAD risk fac-
tors. These findings are important because HIV-
positive populations have a high number of CVD
risk factors including smoking,3 hypertension,3 di-
abetes,3 hyperlipidemia,3 metabolic syndrome,27
insulin resistance,28 and antiretroviral use.29
The mechanisms that might link lower neurocog-
nitive performance with CVD and cardiovascular
risk factors in HIV-positive populations are likely
multifactorial. In HIV-negative populations increas-
ing evidence suggests that cardiovascular risk factors
contribute to the pathogenesis of both vascular de-
mentia and AD.4-6,30 Theoretically the pathogenesis
of these 2 dementing illnesses may overlap. Recently
it was proposed that insulin resistance, which under-
lies several of the abovementioned cardiovascular risk
factors, may be one of the primary convergent mech-
anisms that links these risk factors to both vascular
dementia and AD.31
Raised inflammatory markers, including IL-6 and
C-reactive protein, are risk factors for dementia32 and
are common to CVD,33 the metabolic syndrome,34
aging, and HIV, including treated HIV infection.35
However, we do not have inflammatory markers for
study analysis.
The changes in the adaptive immune system of
HIV-infected patients receiving long-term antiretro-
viral therapy resemble those seen in the elderly.36 Key
factors that may contribute to immune senescence in
HIV-infected patients include persistent immune ac-
tivation, inflammation, and poor CD4 cell response
to antiretroviral treatment.36 A recent study of HIV-
infected patients measured coronary artery calcium
accumulation and found an increased vascular age in
over 40% of patients, with a mean increase of 15
years over their chronological age.37 Increased vascu-
lar aging would help to explain why we found an
association between lower neurocognitive perfor-
mance and cardiovascular risk factors/CVD in a rela-
tively young study population whereas cognitive
decline and dementia associated with these factors in
HIV-negative populations usually do not occur until
at least the sixth decade. Similarly, the early expres-
sion of Parkinson disease in HIV infection has been
reported recently.38
None of the conventional HIV-related HAD risk
factors was associated with NCI or lower neurocogni-
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tive performance and the reason for this is unclear. The
median CD4 cell count was high (536 cells/mm3) but
there was also no association of NCI with nadir CD4
counts. There was no evidence for an association of dia-
betes with impairment or poorer neurocognitive perfor-
mance, although the lack of evidence may have been
due to the low number of participants with diabetes.
There was also no evidence for an association of the
ART CNS penetration effectiveness rank with any of
the neurocognitive performance scores. ART regimens
with CNS penetration effectiveness ranks 2 have been
associated with improved neurocognitive perfor-
mance26; in our study, 25% of participants had CNS
penetration effectiveness ranks 2. Contrary to expec-
tations, participants with prior AIDS had a slightly in-
creased estimated mean QNPZ-5 score (by 0.24, p 
0.05, table 3). This may be a statistical artifact due to
confounding; in univariate analysis, those with and
without prior AIDS had similar QNPZ-5 scores (p 
0.60 for difference), but those with prior AIDS had
more CVD risk factors, including a higher body mass
index (mean 25 vs 23) and more use of BP-lowering
drugs (18% vs 9%).
Mean z scores differed significantly between loca-
tions for each of the 5 neurocognitive tests; more-
over, differences between locations persisted after
adjusting for differences in age, sex, race, and educa-
tion and other factors (table 3). At first glance, this
leads to the hypothesis that the standard US norms
were not appropriate for Brazil or Thailand. Within
countries, however, z scores also varied considerably
between clinical sites (table 2, hierarchical model).
Further adjustment for age, race, sex, and education
decreased between-site variability in raw test scores,
but had only minimal effect on the between-site vari-
ability in z scores (data not shown). The latter sug-
gests that our US norm z scores reasonably
standardized the test scores for these 4 demographic
factors, and that the remaining variability between
countries may be largely due to other unmeasured
factors such as nutritional status, urban vs rural resi-
dency, cultural/ethnic factors, and test administra-
tion. It may be that if we had been able to more
accurately measure and adjust for the education of
participants, for example by assessing their reading
level39 instead of using years of education, we may
have seen less between-country variability.
Twenty-four percent of participants met the
study definition of depression; this proportion is
commensurate with some studies but lower than oth-
ers.15 Antidepressant use was not assessed.
One should interpret our study definition of NCI
(z scores 2 in 2 or more domains) with caution
because 1) NCI was not confirmed clinically; 2) we
used US norms in Brazilian and Thai populations;
and 3) we assessed 4 cognitive domains only.19 More-
over, NCI may not always represent HAD or other
HIV-associated neurocognitive disorders because
there is an overlap between the neurocognitive im-
pairment associated with cerebrovascular disease40
and HIV-associated CNS disease.
Study limitations include a moderate sample size,
which limits the power to detect associations; a mod-
est test battery; study-trained staff rather than neuro-
psychologists administering the neurocognitive tests;
and the lack of local reference norms in Brazil and
Thailand. Also, hypertension was not assessed di-
rectly, but extrapolated from the use of BP-lowering
drugs. Finally, we evaluated multiple outcomes;
some of the observed associations might be false-
positives, in particular where statistical significance
was borderline.
Our findings suggest that, in HIV-infected per-
sons with high CD4 cell counts, cardiovascular-
related insults may be more detrimental to
neurocognitive functioning than factors more di-
rectly related to HIV. Given the high prevalence of
cardiovascular risk factors in HIV-infected popula-
tions, this finding is important and warrants further
investigation.
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Editor’s Note to Authors and Readers: Levels of Evidence coming to Neurology®
Effective January 15, 2009, authors submitting Articles or Clinical/Scientific Notes to Neurology® that report on clinical
therapeutic studies must state the study type, the primary research question(s), and the classification of level of evidence assigned
to each question based on the classification scheme requirements shown below (left). While the authors will initially assign a
level of evidence, the final level will be adjudicated by an independent team prior to publication. Ultimately, these levels can be
translated into classes of recommendations for clinical care, as shown below (right). For more information, please access the
articles and the editorial on the use of classification of levels of evidence published in Neurology.1-3
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